

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**建業地產股份有限公司\***

**Central China Real Estate Limited**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 0832)

**SUPPLEMENTAL ANNOUNCEMENT  
IN RELATION TO THE  
2021 ANNUAL REPORT**

Reference is made to the annual report for the year ended 31 December 2021 (the “**2021 Annual Report**”) of Central China Real Estate Limited (the “**Company**”). Terms used herein shall have the same meanings as defined in the 2021 Annual Report unless otherwise stated.

In addition to the disclosures under the section headed “Share Option Scheme” in the Directors’ Report and Note 31 to the consolidated financial statements as set out in the 2021 Annual Report, the Company would like to provide the following additional information in relation to the share option schemes of the Company (the “**Scheme**”) pursuant to Rules 17.07, 17.08 and 17.09 of the Listing Rules.

As of 31 December 2021, the total number of shares available for issue under the Scheme, for which the underlying share options (the “**Share Options**”) have been approved by the shareholders but are yet to be granted by the Company, is 143,926,256 shares, representing approximately 4.86% of the issued share capital of the Company.

On 20 August 2021, the Company granted a total of 137,000,000 Options under the Scheme to certain eligible participants, being senior management and employees of the Group. The fair value representing the Options granted to the eligible participants on the date of grant were approximately HK\$64,650,300. The closing price of the shares of the Company immediately before the date of grant of the Options was HK\$1.93.

The vesting period for each grant of Options set out on page 154 and page 155 of the 2021 Annual Report is represented by the period between the date of grant and the commencement of the exercise period. The table set forth below sets out additional details on the vesting period of each grant of Options, please refer to page 154 and page 155 of the 2021 Annual Report for additional information on the grant of Options.

<b>Name or category of participants</b>	<b>Date of grant</b>	<b>Exercise price per Share</b>	<b>Exercise and vesting period (Notes)</b>
<b>Directors</b>			
Mr. Wang Jun (resigned on 1 August 2022)	23 August 2018	HK\$3.470	6
Ms. Wu Wallis (alias Li Hua) <sup>8</sup>	27 March 2013	HK\$2.560	3
	23 May 2017	HK\$1.764	4
Ms. Chen Ying (resigned on 1 August 2022)	12 June 2018	HK\$4.296	5
<b>Chief Executive Officer</b>			
Mr. Wang Jun (ibid.) (resigned on 14 February 2022)			
Mr. Yang Mingyao (appointed on 14 February 2022)	27 March 2013	HK\$2.560	3
	12 June 2018	HK\$4.296	5
Senior Management and other employees of the Group	25 July 2011	HK\$2.160	2
	27 March 2013	HK\$2.560	3
	23 May 2017	HK\$1.764	4
	12 June 2018	HK\$4.296	5
	23 August 2018	HK\$3.470	6
	20 August 2021	HK\$1.890	7

*Notes:*

1. In relation to each grantee of the Option granted under the Scheme, no share option is exercisable within the first year from the respective dates of grant, that is, 25 July 2011, 27 March 2013, 23 May 2017, 12 June 2018 and 23 August 2018 (the “**Dates of Grant**”), not more than 20% of the share options are exercisable within the second year from the respective Dates of Grant and not more than 40% of the share options are exercisable in each of the third and fourth year from the respective Dates of Grant.
2. The share options are divided into 3 tranches exercisable from 25 July 2012, 25 July 2013 and 25 July 2014 respectively to 24 July 2021. The vesting period of the 3 tranches begins on 25 July 2011 and ends on 24 July 2012, 24 July 2013 and 24 July 2014, respectively.
3. The share options are divided into 3 tranches exercisable from 27 March 2014, 27 March 2015 and 27 March 2016 respectively to 26 March 2023. The vesting period of the 3 tranches begins on 27 March 2013 and ends on 26 March 2014, 26 March 2015 and 26 March 2016, respectively.
4. The share options are divided into 3 tranches exercisable from 23 May 2018, 23 May 2019 and 23 May 2020 respectively to 22 May 2027. The vesting period of the 3 tranches begins on 23 May 2017 and ends on 22 May 2018, 22 May 2019 and 22 May 2020, respectively.
5. The share options are divided into 3 tranches exercisable from 12 June 2019, 12 June 2020 and 12 June 2021 respectively to 11 June 2028. The vesting period of the 3 tranches begins on 23 May 2017 and ends on 22 May 2018, 22 May 2019 and 22 May 2020, respectively.
6. The share options are divided into 3 tranches exercisable from 23 August 2019, 23 August 2020 and 23 August 2021 respectively to 22 August 2028. The vesting period of the 3 tranches begins on 23 August 2018 and ends on 22 August 2019, 22 August 2020 and 22 August 2021, respectively.
7. The share options are divided into 3 tranches exercisable from 20 August 2022, 20 August 2023 and 20 August 2024 respectively to 19 August 2031. The vesting period of the 3 tranches begins on 20 August 2021 and ends on 19 August 2022, 19 August 2023 and 19 August 2024, respectively.
8. The 44,000 Options are beneficially owned by the spouse of Ms. Wu Wallis (alias Li Hua), therefore Ms. Wu Wallis (alias Li Hua) is deemed to be interested in her spouse’s share options for the purposes of the SFO.

The above supplemental information does not affect other information contained in the 2021 Annual Report. Save as disclosed above, all other information in the 2021 Annual Report remains unchanged.

By order of the Board  
**Central China Real Estate Limited**  
**Wu Po Sum**  
*Chairman*

Hong Kong, 18 August 2022

*As at the date of this announcement, the Board comprises seven Directors, of which Mr. Wu Po Sum is executive Director, Ms. Wu Wallis (alias Li Hua), Mr. Deng Gaoqiang and Mr. Shi Song are non-executive Directors, Mr. Cheung Shek Lun, Mr. Xin Luo Lin and Dr. Sun Yuyang are independent non-executive Directors.*

\* *For identification purposes only*